Paricalcitol, a vitamin D receptor activator, inhibits tumor formation in a murine model of uterine fibroids

Sunil K. Halder, Chakradhari Sharan, Omar Al-Hendy, Ayman Al-Hendy

Research output: Contribution to journalArticlepeer-review

47 Scopus citations


We examined the antitumor and therapeutic potentials of paricalcitol, an analog of 1,25-dihydroxyvitamin D3 with lower calcemic activity, against uterine fibroids using in vitro and in vivo evaluations in appropriate uterine fibroid cells and animal models. We found that paricalcitol has potential to reduce the proliferation of the immortalized human uterine fibroid cells. For the in vivo study, we generated subcutaneous tumors by injecting the Eker rat-derived uterine leiomyoma cell line (ELT-3) rat uterine fibroid-derived cell line in athymic nude mice supplemented with estrogen pellets. These mice were administered with vehicle versus paricalcitol (300 ng/kg/d) or 1,25-dihydroxyvitamin D3 (500 ng/kg/d) for 4 consecutive weeks, and the data were analyzed. We found that while both paricalcitol and 1,25-dihydroxyvitamin D3 significantly reduced fibroid tumor size, the shrinkage was slightly higher in the paricalcitol-treated group. Together, our results suggest that paricalcitol may be a potential candidate for effective, safe, and noninvasive medical treatment option for uterine fibroids.

Original languageEnglish (US)
Pages (from-to)1108-1119
Number of pages12
JournalReproductive Sciences
Issue number9
StatePublished - Sep 1 2014


  • 1,25-dihydroxyvitamin D3
  • Zemplar
  • leiomyoma
  • paricalcitol
  • uterine fibroids
  • vitamin D3

ASJC Scopus subject areas

  • Obstetrics and Gynecology


Dive into the research topics of 'Paricalcitol, a vitamin D receptor activator, inhibits tumor formation in a murine model of uterine fibroids'. Together they form a unique fingerprint.

Cite this